Mixed Q2 results and projections failed to both impress and reassure investors. Short-term pressure is expected due to uncertainties around Defence contracts and a διευθны outlook. Continued portfolio and geographic diversification efforts are positive, but the absence of clear long-term guidance fails to offer reassurance. The withdrawal of a key drug candidate and focus on cost-cutting also counts against the immediate stock outlook. [-1]